Sagimet Biosciences (SGMT) KOL event summary

Introduction and agenda

• Virtual KOL event hosted to review 52-week Phase 3 open-label extension data for denifanstat in moderate to severe acne and provide an update on the upcoming U.S. AURORA Phase 3 trial.

• Event featured a webcast with company management and KOL Julie Harper, MD, on September 30, 2026.

KOL background and credentials

• Julie Harper, MD, is the Founding Director and past President of the American Acne and Rosacea Society.

Market insights and analysis

• Approximately 10 million people in the U.S. suffer from moderate to severe acne annually, with a significant unmet need for new oral therapies.

• Acne affects about 85% of individuals aged 12–24, with 20% experiencing moderate to severe forms.